Founder & Executive Chairperson at Biocon
Indian VCs are willing to invest in safe, copycat service companies, but they avoid backing cutting-edge innovation. Pre-revenue and clinical-stage companies cannot list on Indian exchanges to raise scale-up capital, forcing our best innovators to sell their technologies to foreign buyers.
This answer is part of a full interview with Kiran Mazumdar-Shaw, Founder & Executive Chairperson at Biocon.
Found this insight valuable? Share it with your network to help others learn from Kiran Mazumdar-Shaw's experience.
Use this answer in your research, article, or academic work
